



CIRRUSDX

**PRELIMINARY**

Accession #: W2026-000021

Name: Clark, Betty

DOB: 7/12/1952

MRN/SSN:

Sex: Female

Laboratory Information	Sample Information	Practice Information
<p><b>CirrusDx, Inc</b> 77 Upper Rock Circle, 4<sup>th</sup> Floor Rockville, MD 20850</p> <p>CLIA# 21D2130541</p> <p>Dr. Todd Myers, Lab Director 240-813-8801 or reports@cirrusdx.com</p>	<p><b>Technician:</b> CWS</p> <p><b>Date Collected:</b> 3/1/2026 <b>Date Received:</b> 3/2/2026 <b>Date Reported:</b> 3/2/2026</p> <p><b>Reporting Method:</b> EMR</p>	<p><b>Name:</b> Apple Urology</p> <p><b>Provider:</b> Physician, One <b>Address:</b> 123 Apple Way Farmville MD 12345 <b>Phone:</b> 987-654-3210 <b>Fax:</b> (301) 621-4254 <b>Email:</b> results@appleurology.com</p>

Test Information: Wound Infection Panel (WIP™) & Culture Based AST (polyMIC™)				
<b>Specimen Type:</b>	Wound Swab	Right Foot	<b>Antibiotic Usage:</b>	Unknown

Detected pathogens, as determined by Wound Infection Panel (WIP™)		
Organism Name	Classification	Detection Level (Organism/mL)
Acinetobacter baumannii	Gram Negative	1x10 <sup>6</sup>
Escherichia coli	Gram Negative	1x10 <sup>6</sup>
Anaerococcus spp.	Gram Positive	1x10 <sup>6</sup>
Enterococcus faecalis	Gram Positive	1x10 <sup>6</sup>

**PRELIMINARY REPORT. polyMIC™ (antibiotic susceptibility testing) is being processed and results are expected within 72 hours. A final report will be sent once completed.**

General Comments
None.



CIRRUSDX

PRELIMINARY

Accession #: W2026-000021
Name: Clark, Betty
DOB: 7/12/1952
MRN/SSN:
Sex: Female

Notes:

Questions including Clinical Consultation on Results: 240-813-8801 or reports@cirrusdx.com

Organism Tested (Reference Range):

Table with 2 columns: Organism List and Reference Range. Reference Range is listed next to each organism. Includes organisms like Acinetobacter baumannii, Klebsiella oxytoca, etc.

#Due to the complexity of the bacteria genus, there may be other species that are detected in the assay that are not listed.

Organisms/mL: are based on the calculation of genome equivalents. One genome equivalent is theoretically equal to one colony forming unit (cfu).

WIP™ test method: Wound Infection Panel, Real-Time PCR.

polyMIC™ test method: Antibiotic susceptibility testing is performed by using culture. Reference range for antibiotics are susceptible.

Halo (H): is the result of both Sensitive and Resistant organisms responding to an antibiotic.

Sensitive (S): indicates the organism(s) is susceptible to the antibiotic.

S: This bacteria/antibiotic combination has been found to be susceptible in >95% of the strains tested. This result was not derived from in-house culture methodology. The antibiotic sensitivity interpretation was determined using CLSI M100 Appendix D: Anaerobe Cumulative Antibiogram, which utilizes culture-based findings compiled from various institutions.

Intermediate (I): indicates the organism(s) is susceptible to the antibiotic but not at a level required to ensure effectiveness.

Resistant (R): indicates the organism(s) is not susceptible (resistant).

Intrinsic Resistance (iR): bacterium is known to be intrinsically resistant to this antibiotic.

Black Spaces in polyMIC™ Tables: are there for the following reasons: the antibiotic was not cleared by the FDA for use with that bacterium, there is insufficient evidence in the literature to support using that antibiotic for that bacterium, and/or that antibiotic has been shown in the literature to not be effective against that bacterium. Laboratory susceptibility does not always predict clinical outcomes.

It is the physician's responsibility to interpret the results provided and determine the appropriate (if any) treatment options including antibiotic selection.

The assays were developed and their performance characteristics were determined by CirrusDx. They have not been cleared or approved by the US Food and Drug Administration. The FDA does not require these tests to go through premarket FDA review. This test is used for clinical purposes. It should not be regarded as investigational or for research.

This report has been reviewed and approved by:

Todd Myers (signature)

Dr. Todd Myers, Laboratory Director.